Serum levels of substance P are decreased in patients with type 1 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 3, 2000, Pages 164-167

  Kunt, T ^a,b   Forst, T ^a   Schmidt, S ^a   Pfutzner A ^a   Schneider, S ^a   Harzer, O ^a   Lobig M ^a   Engelbach, M ^a   Goitom, K ^a   Pohlmann, T ^a   Beyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Dept of Int Med and Endocrinology   (Germany)

Author keywords

Diabetes mellitus; Neuropathy; Serum level; Substance P

Indexed keywords

CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SUBSTANCE P; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; REFERENCE VALUES; SUBSTANCE P;

EID: 12944272082     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-7738     Document Type: Article

References (26)

1. Bloom SR, Polak JM, Laybourn PJ, Najarian RC: Regulatory peptides and the skin. Clin Exp Dermatol 8: 3-18, 1983
2. 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 27: 245-249, 1987
3. Boden G, Master RW, Owen OE, Rudnick MR: Human pancreatic polypeptide in chronic renal failure and cirrhosis of the liver: role of kidneys and liver in pancreatic polypeptide metabolism. J Clin Endocrinol Metab 51: 573-578, 1980
4. Chang MM, Leeman SE, Nrall HD: Amino acid sequence of substance P. Nature 232: 86-87, 1971
5. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC: Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 88: 70-78, 1989
6. Conlon JM, Deacon CF, Richter G, Stcökmann F, Creutzfeldt W: Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 22: 97-105, 1987
7. Dalsgaard CJ, Johnsson CE, Hökfelt T, Cuello AC: Localization of substance P-immunoreactive nerve fibers in the human digital skin. Experientia 39: 1018-1020, 1983
8. Davidson WD, Springberg PD, Falkinburg NR: Renal extraction and excretion of endogenous gastrin in dog. Gastroenterology 64: 955-961, 1973
9. Eedy DJ: Neuropeptides in skin. Br J Dermatol 128: 597-605, 1993
10. Hegbrant J, Thysell H, Ekman R: Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment. Scand J Urol Nephrol 26: 169-176, 1992
11. Kastrup J, Henriksen JH, Pedersen JH, Fahrenkrug J, Schaffalitzky de Muckadell OB, Schwartz T, Parving HH, Christensen NJ: Effect of ganglionic blockade on endogenous circulating pancreatic polypeptide, vasoactive intestinal polypeptide, substance P, neurotensin and noradrenaline in healthy controls and long-term insulin-dependent diabetic patients. Clin Sci 71: 411-419, 1986
12. Katz AI, Rubenstein AH: Metabolism of proinsulin, insulin and c-peptide in the rat. J Clin Invest 52: 1113-1121, 1973
13. Levy DM, Karanth SS, Springall DR, Polak JM: Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: an immunocytochemical study. Diabetologia 32: 427-433, 1989
14. Lindberger M, Schroder HD, Schultzberg M, Kristensson K, Persson A, Ostman J, Link H: Nerve fiber studies in skin biosies in peripheral neuropathies. I. Immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci 93: 289-296, 1989
15. Lysy J, Karmeli F, Goldin E: Substance P levels in the rectal mucosa of diabteic patients with normal bowel function and constipation. Scand J Gastroenterol 28: 49-52, 1993
16. Marshall KW, Chiu B, Inman RD: Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum 33: 87-90, 1990
17. Mori K, Asakura S, Morokawa N, Takeyama M: Effect of terfenadine on the plasma concentrations of substance P and vasoactive intestinal polypeptide in volunteers. J Pharm Pharmacol 44: 856-858, 1992
18. Said SI: Vasoactive peptides. State-of-the-art review. Hypertension 5, Suppl 1: 117-26, 1983
19. Saria A: Neuropeptide. Hautarzt 43: 745-752, 1992
20. Schaffalitzky de Muckadell OB, Aggestrup A, Stentoft P: Flushing and substance P concentration during infusion of synthetic-substance P in normal man. Scand J Gastroenterol 21: 498-502, 1986
21. Schmidt RE, Dorsey DA, Roth KA: Immunohistochemical characterization of NPY and substance P containing nerve terminals in aged and diabetic human sympathic ganglia. Brain Res 583: 320-326, 1992
22. Snyder SH: Brain peptides as neurotransmitters. Science 209: 976-983, 1980
23. Tanio H, Vaalasti A, Rechardt L: The distribution of substance P-, CGRP-, galanin- and ANP-like immunoreactive nerves in human sweat glands. Histochem J 19: 375-380, 1987
24. Thysell H, Grubb A, Lindholm T, Ljunggren L, Martenson L: Cystatin C: a new marker of biocompatibility or a good marker for the redistribution of LMW proteins during hemodialysis? Trans Am Soc Artif Intern Organs 34: 202-204, 1988
25. Valdemarsson S, Edvinsson L, Ekman R, Hedner P, Sjöholm A: Increased level of substance P in patients with severe congestive heart failure treated with ACE inhibitors. J Int Med 230: 325-331, 1991
26. Von Euler VS, Gaddum JH: An unidentified depressor substance in certain tissue extracts. J Physiol (London) 72: 74-87, 1931